Gamma-hydroxybutyrate overdose and coma: a case report

Meite S. Moser, MD; Roy A. Purssell, MD

Introduction

Gamma-hydroxybutyrate (GHB) has become a common drug of abuse. It is especially popular at rave parties, where many people can be exposed at one time. GHB is also used by body builders as an anabolic agent, and has reportedly been used as a date-rape drug. Currently it is being investigated for several legitimate medical applications, including narcolepsy treatment and alcohol or opioid withdrawal. GHB should be considered when a patient presents to the emergency department (ED) with undifferentiated coma.

Case report

A 44-year-old male was sitting in a chair at work when he stiffened and collapsed. Paramedics arrived several minutes later and found him unresponsive with pinpoint pupils. There was no witnessed seizure activity. He was given naloxone with no observed response. Because he had vomited and was not protecting his airway, the paramedics attempted intubation with sedation. Despite being administered 20 mg of midazolam in incremental doses, he aroused with each intubation attempt; 6 unsuccessful attempts were made prior to transport. On arrival in the ED he was afebrile and normotensive with a heart rate of 74 beats/min. Pupils were pinpoint, his Glasgow coma score was 3, and he was receiving assisted ventilation. Initial management included rapid sequence intubation and intubation. Complete blood count, electrolytes, and arterial blood gases were normal, and an urgent CT revealed no abnormalities.

Several hours later, the patient became abruptly responsive and agitated, then gradually more cooperative. After extubation, he admitted that he had ingested GHB. The friend who gave him the drug had assured him that GHB was previously available in health food stores and that it would make him feel “good.” Because he is a large man, he took a larger dose than his friend recommended. He remembered feeling good with a “body high” shortly after the ingestion, but was unable to remember the rest of the incident. He was observed overnight and discharged, feeling well, in the morning.

Discussion

GHB was first used medically in the 1960s as an anesthetic agent. It is chemically similar to gamma-aminobutyric acid (GABA) and rapidly crosses the blood–brain barrier (Fig. 1). Because of its unpredictable action and lack of analgesic activity it was quickly abandoned as an anesthetic agent. In 1988, following the FDA ban on L-tryptophan,
GHB became a popular over-the-counter sedative agent. The body building community also used it heavily for its (unproven) anabolic effects. During a 6-month period in 1990 there were 57 case reports of illness attributed to GHB, which prompted the FDA to issue a warning on its use and to ban over-the-counter sales.

Currently, GHB is an investigational drug for the treatment of narcolepsy, and published trials suggest that GHB reduces all narcolepsy-related symptoms. GHB increases delta sleep and improves the continuity of sleep in both normal and narcoleptic patients. Its major side effect in narcoleptic patients is sleepwalking, which naturally occurs during periods of delta sleep. Of interest, growth hormone is normally released during delta sleep, and it may be for this reason that GHB is promoted as an anabolic agent, although there is no evidence to support its effectiveness as such. GHB shows some promise in the settings of alcohol and opioid withdrawal.

On the street, GHB is sold under a multitude of names (Table 1). It is one of the most popular drugs at rave parties and is favoured for its euphoriant effect. It has also been reported to cause sexual stimulation and has several properties that have led to its use as a “date rape” drug. It is highly soluble, colourless and tasteless in the powder form, and it causes an irresistible desire to drink. Furthermore, there is no hangover effect and it is difficult to detect. GHB is addictive, and several case reports document withdrawal symptoms upon cessation of use. These symptoms, typically anxiety, tremulousness and insomnia, subside within a week of discontinuing use.

One reason for its popularity is easy accessibility. GHB can be synthesized in any home lab by ester hydrolysis of gammabutyrolactone (GBL) (a common wood cleaner, paint remover and textile aid), in the presence of sodium hydroxide or lye. Several Internet sites provide simple directions how to make GHB in the home kitchen. With these instructions and $800 worth of raw materials, one can manufacture GHB with a street value of $92,000. Improper preparation, though, can cause severe toxic reactions, including caustic burns related to sodium hydroxide.

With increasing doses, GHB causes drowsiness, amnesia, bradycardia, coma, respiratory depression and, in some cases, cardiorespiratory collapse (Table 2), although there is no reliable diagnostic test. Lab analysis, particularly forensic analysis, is difficult, and current testing methods may be unreliable. In addition, it is unclear what “normal” GHB levels are, and there may be post-mortem production, leading to false-positive tests.

### Conclusions

GHB use is increasing. Clinicians should consider GHB when patients present with coma of unknown origin. Selected clinical findings may suggest GHB overdose but there is no reliable diagnostic test. Supportive care, particularly airway control, is the key to management.

### Key words: GHB, gamma-hydroxybutyrate, overdose.

### Table 1. Street names for gamma-hydroxybutyrate (GHB)

<table>
<thead>
<tr>
<th>Gamma-OH</th>
<th>Liquid X</th>
<th>Soap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Easy Lay</td>
<td>Liquid Ecstasy</td>
<td>Somatomax PM</td>
</tr>
<tr>
<td>Everclear</td>
<td>Nature’s Quaalude</td>
<td>Somsanit</td>
</tr>
<tr>
<td>Georgia Home Boy</td>
<td>Oxy-sleep</td>
<td>Vita-G</td>
</tr>
<tr>
<td>Grevious Bodily Harm</td>
<td>Poor Man's Heroin</td>
<td>Water</td>
</tr>
<tr>
<td>Great Hormones at Bedtime</td>
<td>Salt water</td>
<td>Wolfies</td>
</tr>
<tr>
<td>Goops at Bedtime</td>
<td>Scoop</td>
<td>Zonked</td>
</tr>
</tbody>
</table>

### Table 2. GHB toxicity and dose-response

<table>
<thead>
<tr>
<th>Dose, mg/kg</th>
<th>Clinical effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Short-term amnesia, hypotonia</td>
</tr>
<tr>
<td>20–30</td>
<td>Drowsiness, sleep</td>
</tr>
<tr>
<td>50–70</td>
<td>Hypnosis, bradycardia, hypopnea, coma, decreased cardiac output</td>
</tr>
<tr>
<td>&gt;70</td>
<td>Possible cardiorespiratory collapse, arrest</td>
</tr>
</tbody>
</table>
References
2. Armstrong N. Deadly drugs surface on Vancouver rave scene. Vancouver Sun 1999 Feb 6; Sect A:1,2.

Correspondence to: Dr. Meite Moser, Emergency Department, Vancouver Hospital, 855 W 12th Ave., Vancouver BC V5Z 1M9; mmoser@interchange.ubc.ca

The best place for your landmark article

New journals face a critical catch-22. The National Library of Medicine (MEDLINE) will not index a new journal until it is publishing high quality scientific material, but authors would rather not submit high quality scientific articles to a new journal until it is indexed. Consequently, one of the big challenges for any new journal is to attract good authors and high quality articles. Authors want their work to reach the largest possible audience, and want their article catalogued in a searchable electronic database so future readers and researchers can reference it easily. While CJEM is not yet an indexed journal, we have addressed both these issues. In terms of visibility, CJEM is distributed to all Canadian emergency physicians and residency programs, giving it the largest Canadian readership of any EM journal. In addition, CJEM is distributed to over 150 US residency programs and to Canadian expatriates and “prominent” emergency physicians in Europe, Asia, Africa, Australia and the Middle East. Current CJEM distribution is 7,500 copies per issue, which compares favourably to other EM journals. Only Annals of Emergency Medicine has a substantially larger readership base and, of course, it does not come with an attractive teal cover or any kind of decent humour section.

To ensure that our articles reach an international audience, CJEM is the only EM journal freely available in full text format on the World Wide Web. This increases North American exposure and international penetration. While the exact level of the increase is unclear, some marketing experts suggest that a journal published on the Web will reach up to 10 times as many readers as the corresponding hard-copy journal. We therefore believe that articles published in CJEM will be read by more people than articles published in any other EM journal.

In addition, complimentary CJEM issues go to Drs. Jerry Hoffman and Rick Bukata, so that our articles can be reviewed on Emergency Medical Abstracts (EMA) tapes and enter the EMA database — perhaps the most useful article database for emergency physicians.

After our first full year of publication we became eligible to apply for National Library of Medicine indexing. While this is not a “sure thing,” we have been told that, based on the quality of the journal so far, CJEM is likely to be accepted. If so, then articles published prior to indexing will be retrospectively added to the MEDLINE database. In the interim, our articles are available to anyone who performs an Internet search.

For now, the New England Journal of Medicine remains the more prestigious of the 2 journals, but those days are numbered. If you have a landmark article and no connections in Boston, remember that CJEM offers peer-review publication, a large reading audience, and — maybe — a free tee-shirt (we’re still thinking about this one).